Clinical Trial

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Study acronym: SEE-D
Recruiting
View on ClinicalTrials.gov →
Summary
The aim is to assess the efficacy and specific safety in an observational study of patients with Chronic hepatitis D (CHD) with prospective follow-up, with antiviral treatment of 2 mg Bulevirtide (BLV) +/- PEG-IFNα-2a and +/- NA given as part of the patient's routine medical care. Also, explorative endpoints of biomarkers in peripheral blood, saliva, fecal sample and/or intrahepatic markers/signatures, and quality of life outcomes will be assessed.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-18.
Status change: Not Yet Recruiting → Recruiting 2023-09-27
Trial Details
NCT Number NCT06051045
Lead Sponsor Karolinska University Hospital
Conditions Chronic Hepatitis D
Enrollment 400 participants
Start Date 2023-09-27
Primary Completion 2033-03 (estimated)
Study Completion 2033-03 (estimated)
Updated on ClinicalTrials.gov 2023-09-29